Dutch survey: E-cigarettes containing synthetic cannabinoids are rampant in schools, endangering the health of minors

Sep.12.2025
Dutch survey: E-cigarettes containing synthetic cannabinoids are rampant in schools, endangering the health of minors
An investigation by Dutch program Zembla found THC e-cigarettes with synthetic cannabinoids spreading quickly among schoolchildren. Lab tests confirmed the products are high-risk and potent, having caused students to vomit, faint, or be hospitalized. Addiction clinics report rising cases, and health officials warn educators of serious health and addiction risks.

Key points:

 

The crux of the issue:

·Illegal THC e-cigarettes containing synthetic cannabinoids have been banned by the Dutch Opium Act since July 2025.

 

Serious danger:

·This has resulted in health issues for students, such as vomiting, fainting, hospitalization, as well as long-term loss of vitality, severe withdrawal symptoms, and mental confusion.

 

Distribution channels:

·Students mainly place orders with drug dealers through social media platforms such as Snapchat, and e-cigarettes can be delivered to the campus within half an hour. 

·Many students mistakenly believe they are purchasing "marijuana e-cigarettes" and are unaware that they are actually using synthetic drugs.

 

Various parties responded:

·Medical institutions have issued an official warning, stating that it has led to "serious health issues." 

·Addiction clinics report that the number of related cases in the Netherlands is increasing. 

·Politicians and experts are calling for immediate action to curb its spread among young students.

 

International background:

·Similar issues have long been present in the UK, with studies showing that one in six e-cigarettes on campus contain synthetic drugs of the same kind.

 


 

In a report by BNNVARA on September 11, 2025, it was revealed that THC e-cigarettes often contain synthetic drugs produced in illegal labs. Schools have reported serious accidents caused by THC e-cigarettes to the Dutch investigative program Zembla, including children vomiting, fainting, and even requiring hospitalization. Last week, Jellinek and the Amsterdam Municipal Health Service (GGD) issued a warning to those working with adolescents, as e-cigarettes may lead to "serious health problems.

 

Outgoing State Secretary for Prevention and Sports, Judith Tielen, expressed concerns about the rise of THC e-cigarettes. She stated, "We are talking about truly harmful illegal substances. In addition to the direct risks, this method of consumption could also act as a gateway to using other substances.

 

Pulmonologist Danielle Cohen and a group of doctors have been battling the proliferation of e-cigarettes among students for years. In response to Zembla's investigation, she said, "This is an extremely dangerous drug, primarily used by prisoners and homeless individuals. If it is now being found that 12-13 year old students are also using e-cigarettes, then we really need to sound the alarm. This situation needs to be addressed quickly.

 

Zembla obtained several e-cigarettes used by students, which were tested in a specialized laboratory for tetrahydrocannabinol (THC). Almost all e-cigarettes were found to contain synthetic cannabinoids. These substances have a stronger potency and greater risks compared to natural cannabis (such as marijuana joints), leading to anxiety, palpitations, and mental confusion. Since July 2025, synthetic cannabinoids and other synthetic designer drugs have been banned under the "Opium Act.

 

A study by Zembla has found that Dutch students are using or familiar with e-cigarettes containing THC. Students report ordering illegal e-cigarettes through social media platforms like Snapchat. Drug dealers are able to deliver the e-cigarettes to campuses within half an hour. Surprisingly, students often do not realize they are vaping synthetic drugs. They mistakenly believe they are using a "marijuana e-cigarette.

 

The three largest addiction treatment clinics in the Netherlands - Jellinek, Novadic-Kentron, and Brijder - appear to have received reports of health issues among young people due to the use of tetrahydrocannabinol (THC) e-cigarettes. Youssef el Markhous, a prevention expert at Jellinek, stated that in recent months, such cases have increased: "This is a concerning development. Initially, we only received reports occasionally, but gradually, the reports have become more frequent and are coming from various regions. We have heard that young people have almost lost their vitality, are unable to move forward, cannot handle stimulation, and even faint. Sometimes very serious withdrawal symptoms also occur.

 

Last week, the Public Health Service of Yerevan and Amsterdam (GGD) sent out a warning email urging people to be cautious about the use of THC e-cigarettes among young people, as this could lead to "serious health issues." Trimbos Institute told Zembla that they have been conducting research on e-cigarettes with strong psychoactive effects, including THC e-cigarettes.

 

In the UK, THC e-cigarettes have long been a well-known issue among student populations. Christopher Pudney, from the University of Bath, decided to test e-cigarettes after hearing about children experiencing adverse effects from using them. In his testing of hundreds of e-cigarettes, he found that one-sixth of them contained this synthetic drug. Pudney said, "For such a harmful and highly addictive drug, this is a shocking result. We are realizing that these reports of children passing out at school are not isolated incidents.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs data showed that illegal cigarettes and vape products seized during the first seven months of 2026 were valued at about PHP11.68 billion, exceeding the PHP2.516 billion recorded for the full year of 2025. The figures were disclosed by a Bureau of Customs official during a House Committee on Ways and Means hearing on tobacco excise tax reforms. Vape-related seizures were valued at about PHP1.65 billion, with most cases recorded at the Manila International Container Port. Customs officials said enforcement against illicit tobacco trade would continue.
Aug.26
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
The UK’s Vaping Products Duty (VPD), scheduled to take effect in October 2026, is prompting retailers to assess how different vape categories may be affected. UK retailer Vape HQ has estimated potential price changes under the new volume-based tax system, showing that 100ml shortfill e-liquids could see prices rise from around £12.99 to £39.39, a 203% increase, while 2ml prefilled pod vape kits could rise from £5.99 to £6.52, an increase of about 9%. The estimates highlight how a volume-based tax structure creates uneven cost impacts across product categories.
Aug.19
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
VAPORESSO introduced the PRIX MTL pod system in August 2026 in two versions, Filter and NFC. The Filter version allows users to switch between a conventional drip tip and a filter tip, while the NFC version links interchangeable panels to matching on-screen animations. PRIX features a 2,600mAh battery, a 5.5ml pod, a 0.87-inch TFT display and a maximum output of 40W, alongside Dual Mesh Impact Pods capable of operating at two resistance and power configurations. VAPORESSO's French website lists MSRP at $39.99 for the Filter version and $49.90 for the NFC version.
Market
Aug.24 by 2Firsts Perspectives
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14